trelstar has been researched along with Vaginal-Diseases* in 2 studies
1 trial(s) available for trelstar and Vaginal-Diseases
Article | Year |
---|---|
Changes in the size of rectovaginal endometriotic nodules infiltrating the rectum during hormonal therapies.
To evaluate the changes in the volume of rectovaginal endometriotic nodules infiltrating the rectum during 12-month treatment with hormonal therapies.. This prospective, non-randomized, self-controlled clinical trial included patients with rectovaginal endometriotic nodules infiltrating at least the muscularis propria of the rectum, who received one of the following therapies: norethisterone acetate, triptorelin and tibolone, norethisterone acetate and letrozole, desogestrel, sequential oral contraceptive pill. The volume of the nodules was determined by virtual organ computer-aided analysis (VOCAL, GE Healthcare, USA) at baseline and after 6 and 12 months of treatment.. Eighty-three women (90.2 %) completed the 12-month treatment. When compared with baseline values, the volume of the nodules decreased at 6-month (p < 0.001) and 12-month treatment (p < 0.001). After 12-month treatment, the volume of the nodules decreased in all study groups. The volume of the nodules decreased during therapy in 68 women (73.9 %) and increased in 11 women (12.0 %).. 12-month administration of hormonal therapies reduces the volume of rectovaginal endometriotic nodules infiltrating the rectum in the majority of cases. Topics: Adult; Aromatase Inhibitors; Calcium; Cholecalciferol; Contraceptives, Oral, Sequential; Contraceptives, Oral, Synthetic; Desogestrel; Endometriosis; Estrogen Receptor Modulators; Female; Humans; Image Processing, Computer-Assisted; Letrozole; Nitriles; Norethindrone; Norethindrone Acetate; Norpregnenes; Prospective Studies; Rectal Diseases; Treatment Outcome; Triazoles; Triptorelin Pamoate; Ultrasonography; Vaginal Diseases; Vitamins | 2013 |
1 other study(ies) available for trelstar and Vaginal-Diseases
Article | Year |
---|---|
Combined oestrogen-progestin treatment of vaginal haemorrhage following gonadotrophin-releasing hormone agonist therapy of uterine myomas.
Three pre-menopausal women with uterine myomas were treated with leuprolide acetate depot and experienced profuse vaginal bleeding 7-11 weeks after initiation of treatment, despite profound oestradiol suppression. In each case, leuprolide therapy was discontinued and the women were treated with combination oral contraceptives and ferrous sulphate. Vaginal bleeding ceased within 24-48 h of oral contraceptive treatment in all women. Haemoglobin concentrations were restored to normal values and all women underwent definitive surgical treatments after 4-6 weeks of oral contraceptive treatment without the need for homologous blood transfusion. The final pathology report revealed focal necrosis of submucous myomas in all cases. Topics: Adult; Contraceptives, Oral; Delayed-Action Preparations; Drug Therapy, Combination; Estrogens; Female; Ferrous Compounds; Gonadotropin-Releasing Hormone; Hemorrhage; Humans; Leiomyoma; Leuprolide; Middle Aged; Triptorelin Pamoate; Uterine Neoplasms; Vaginal Diseases | 1993 |